The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Eric SolaryDuring the ESH 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to Bedside, the MDS Hub spoke to Eric Solary, Gustave Roussy, Paris, FR. We asked, How does COVID-19 infection affect hematopoiesis in MDS?
How does COVID-19 infection affect hematopoiesis in MDS?
In the majority of COVID-19 infections, the virus induces an effective antiviral, interferon response. However, for a minority with severe disease, a stress hematopoiesis response is detected, preventing patients from building an appropriate immune response. Patients with MDS could be predisposed to the virus since the hematopoietic response in the severe form of COVID-19 resembles that of acute MDS. For that reason, Solary urges patients to remain cautious and get immunized.